Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity.
about
Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient PopulationsRole of cephalosporins in the era of Clostridium difficile infectionCeftobiprole medocaril in the treatment of hospital-acquired pneumoniaResistance and the management of complicated skin and skin structure infections: the role of ceftobiprole.Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.Effect of ceftobiprole treatment on growth of and toxin production by Clostridium difficile in cecal contents of miceCurrent and novel antibiotics against resistant Gram-positive bacteria[Resistance to "last resort" antibiotics in Gram-positive cocci: The post-vancomycin era].Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.Ceftobiprole efficacy in vitro against Panton-Valentine leukocidin production and in vivo against community-associated methicillin-resistant Staphylococcus aureus osteomyelitis in rabbitsPopulation pharmacokinetic analysis of ceftobiprole for treatment of complicated skin and skin structure infectionsCeftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin.Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysisPharmacodynamic profiling of ceftobiprole for treatment of complicated skin and skin structure infectionsCurrent challenges in treating MRSA: what are the options?Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge.Ceftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus.Ceftobiprole: a new broad spectrum cephalosporin.Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections.Exposure to ceftobiprole is associated with microbiological eradication and clinical cure in patients with nosocomial pneumonia.Resistant pathogen-associated skin and skin-structure infections: antibiotic options.Invasive community-associated MRSA infections: epidemiology and antimicrobial management.Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia.Does Secretory Clearance Follow Glomerular Filtration Rate in Chronic Kidney Diseases? Reconsidering the Intact Nephron Hypothesis.One ring to rule them all: Current trends in combating bacterial resistance to the β-lactamsPharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA.Ceftobiprole medocaril (BAL-5788) for the treatment of complicated skin infections.Evaluation of ceftobiprole activity against a variety of gram-negative pathogens, including Escherichia coli, Haemophilus influenzae (β-lactamase positive and β-lactamase negative), and Klebsiella pneumoniae, in a rabbit meningitis model.Ceftobiprole, a Broad-Spectrum Cephalosporin With Activity against Methicillin-Resistant Staphylococcus aureus (MRSA).Efficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureus.In Vitro Activity of Tedizolid, Dalbavancin, and Ceftobiprole Against Clostridium difficile.
P2860
Q28066877-5D60833F-C6B6-4847-B5BC-EBB8C239EA6BQ28078261-AED1475F-6D8D-4A38-8D46-6876303C5941Q28085517-66E900EE-D375-4910-A38B-35A946976F4AQ34187667-E9E2DFEC-D2DB-48AE-AF21-03586FBACB1FQ34433342-9052235A-72AB-4D33-AEDA-5ECFD93A692BQ34932729-FDBE5098-884A-466E-AC3B-8DDFD35939F9Q35026521-F148AA49-D71C-4A68-822F-2C6788D43687Q35619094-BB79ECD0-C15B-4056-AEEA-C28559D80845Q35806369-39CDDF49-CA37-4320-89CF-E6365F0504AFQ36396146-9583802F-74DB-49D3-8BE0-764A1E886713Q37115687-02E20397-81C4-4647-9B50-ED1582FC4BC4Q37162872-BD174B66-73B3-4353-BF17-3AFE9F3B6C2AQ37247602-C1AC876E-E317-42C0-B359-E35705690040Q37274751-6535B6A4-F0BD-4F36-9C29-F113CF48C8D3Q37291338-59AAA3C5-DAEF-4E7F-BE17-F55A0ADB6122Q37392891-1F037955-2504-4BF7-9E9F-4E4F60BC1D6CQ37461413-A854C89F-88B6-4D1C-A383-BEC4761A5B32Q37519733-8F194B54-BDA4-47EB-8E85-D5AA95852F34Q37593094-1C1AFD95-8D2B-41C0-9E8C-F0163C59550AQ37713040-F12A3D50-3CC5-4FB4-B41A-9868256E78F2Q37785546-5DAD893F-DF41-4713-AC1F-404BE54BB862Q37800939-885BE35A-7EC2-4B9E-94C5-6D812F27346FQ38099393-C4A8A7F2-3ED4-4662-A37A-D653AE0BB7AFQ38694525-AF7E5E78-1A58-43ED-B138-385899507A7EQ38712471-C881B19E-A172-4B05-BCC8-DCAE064EF360Q39164183-695765C3-2BD2-4735-95C4-AC32EFC19F20Q39333835-4D9781CA-D51D-42AB-8F30-C7EF9E4FAEDBQ40600643-FE46D46A-B117-451B-B528-3E44D15D5299Q43065479-4CCA4F74-DE38-4341-876C-12F17D128015Q43183402-9012D3B4-3951-4029-94BA-BAACBE22944EQ55282846-97E4E70F-38C2-46E3-AA49-99A8372183B1
P2860
Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacokinetics and pharmacod ...... with broad-spectrum activity.
@en
Pharmacokinetics and pharmacod ...... with broad-spectrum activity.
@nl
type
label
Pharmacokinetics and pharmacod ...... with broad-spectrum activity.
@en
Pharmacokinetics and pharmacod ...... with broad-spectrum activity.
@nl
prefLabel
Pharmacokinetics and pharmacod ...... with broad-spectrum activity.
@en
Pharmacokinetics and pharmacod ...... with broad-spectrum activity.
@nl
P1476
Pharmacokinetics and pharmacod ...... with broad-spectrum activity.
@en
P2093
Anne Schmitt-Hoffmann
Bindu Murthy
P356
10.2165/00003088-200847010-00003
P577
2008-01-01T00:00:00Z
P6179
1002001664